Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR2554 + SHR1701
- Development stage
- Phase 2
- Lead developer
- Jiangsu HengRui Medicine Co., Ltd.
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
SHR2554 + SHR1701 is an investigational combination therapy for cancer. It consists of two agents: - **SHR2554** is a small molecule inhibitor targeting enhancer of zeste homolog 2 (EZH2), an epigenetic regulator implicated in cancer progression. - **SHR1701** (also known as retlirafusp alfa) is a bifunctional recombinant fusion protein that targets programmed death ligand 1 (PD-L1) and acts as a trap for transforming growth factor beta receptor II (TGF-βRII). This dual action blocks immune checkpoint signaling and TGF-beta-mediated immunosuppression. The combination aims to enhance antitumor immunity by both reversing epigenetic silencing of tumor antigens and blocking key immunosuppressive pathways. It has shown encouraging safety and efficacy signals in early-phase clinical trials involving patients with advanced solid tumors and relapsed/refractory classical Hodgkin lymphoma who have received prior immunotherapy[1][2][5].
- Other names
- retlirafusp alfa + SHR2554
02
Targets
EZH2 (Histone-lysine N-methyltransferase EZH2)CD274 (Programmed cell death protein 1 ligand 1)TGFBR2 (TGF-β receptor type 2)
Beyond the preview
Go deeper on SHR2554 + SHR1701.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR2554 + SHR1701.